Inspire Medical Systems (INSP) to Release Quarterly Earnings on Wednesday

Inspire Medical Systems (NYSE:INSP) is expected to be announcing its Q4 2025 results after the market closes on Wednesday, February 11th. Analysts expect the company to announce earnings of $0.70 per share and revenue of $264.0190 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 5:00 PM ET.

Inspire Medical Systems Stock Performance

Shares of Inspire Medical Systems stock opened at $66.39 on Tuesday. The stock has a market capitalization of $1.93 billion, a PE ratio of 45.16, a price-to-earnings-growth ratio of 6.63 and a beta of 0.74. Inspire Medical Systems has a 52 week low of $64.46 and a 52 week high of $197.75. The stock has a 50 day moving average price of $98.68 and a two-hundred day moving average price of $92.29.

Insider Buying and Selling

In other Inspire Medical Systems news, Director Shawn Mccormick sold 2,000 shares of Inspire Medical Systems stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $127.48, for a total transaction of $254,960.00. Following the transaction, the director owned 26,046 shares of the company’s stock, valued at $3,320,344.08. This trade represents a 7.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of INSP. Wasatch Advisors LP increased its position in shares of Inspire Medical Systems by 7.2% during the 2nd quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company’s stock valued at $212,095,000 after purchasing an additional 110,288 shares during the last quarter. Deerfield Management Company L.P. grew its position in Inspire Medical Systems by 648.4% during the third quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock valued at $77,739,000 after buying an additional 907,694 shares during the period. State Street Corp increased its holdings in Inspire Medical Systems by 2.3% during the second quarter. State Street Corp now owns 1,030,902 shares of the company’s stock worth $133,780,000 after buying an additional 22,843 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Inspire Medical Systems by 37.0% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 833,599 shares of the company’s stock worth $61,853,000 after buying an additional 225,291 shares during the last quarter. Finally, Balyasny Asset Management L.P. raised its position in Inspire Medical Systems by 16,504.3% in the third quarter. Balyasny Asset Management L.P. now owns 614,359 shares of the company’s stock worth $45,585,000 after acquiring an additional 610,659 shares during the period. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on INSP shares. Jefferies Financial Group reissued a “hold” rating and issued a $85.00 price target (down previously from $160.00) on shares of Inspire Medical Systems in a research report on Friday, October 24th. Wolfe Research upgraded shares of Inspire Medical Systems from a “peer perform” rating to an “outperform” rating and set a $180.00 price objective for the company in a report on Tuesday, November 25th. Royal Bank Of Canada downgraded shares of Inspire Medical Systems from an “outperform” rating to a “sector perform” rating and decreased their target price for the stock from $175.00 to $90.00 in a research report on Tuesday, January 27th. Oppenheimer cut shares of Inspire Medical Systems from an “outperform” rating to a “market perform” rating in a research report on Thursday, January 22nd. Finally, Robert W. Baird lifted their price target on Inspire Medical Systems from $125.00 to $180.00 and gave the company an “outperform” rating in a research note on Thursday, December 4th. Eight analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $133.47.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.